Wasn’t able to get to a “Top Three” yesterday, as I was attending a (VERY interesting) real-time communications conference in NYC. Blog post coming on that. Meanwhile…
Pfizer, Pfizer, Pfizer. 800 researcher jobs being axed. 100 experimental drugs being sold off in a closeout sale. And, a new (outsider – former General Mills CEO) addition to the board of directors.
Forest gets approval for new fibromyalgia drug Savella. The safety and efficacy of Savella was established in two U.S. pivotal Phase III clinical trials involving over 2,000 patients with fibromyalgia, the companies said.
Eli Lilly handing over 1.42 billion to resolve Zyprexa probes. Eli Lilly and Co said it will pay about $1.42 billion to settle both criminal and civil investigations related to the marketing of its antipsychotic drug Zyprexa and has agreed to plead guilty to one misdemeanor violation of the Food, Drug, and Cosmetic Act.
Live and in-person – the next conference I’ll be attending is the ePharma Summit in Philadelphia, Feb. 9-11. Here’s the scoop.
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Leave a Reply